We report the identification of multitarget anti-Alzheimer compounds designed by combining
a naphthoquinone function and a tacrine fragment. In vitro, 15 compounds displayed …

Multi-target drug discovery is one of the most followed approaches in the active central
nervous system (CNS) therapeutic area, especially in the search for new drugs against …

We have designed a series of tacrine-based homo- and heterodimers that incorporate an
antioxidant tether (selenoureido, chalcogenide) as new dual compounds: for the treatment of …

Microglia, the immune cells of the CNS, play essential roles in both physiological and pathological
brain states. Here we have used an in vitro model to demonstrate neuroprotection of a …

The mitochondrial aspartate-glutamate carrier isoform 1 (AGC1) catalyzes a Ca 2 + -stimulated
export of aspartate to the cytosol in exchange for glutamate, and is a key component of …

Purine nucleoside phosphorylase (PNP), a crucial enzyme in purine metabolism which
converts ribonucleosides into purine bases, has mainly been found inside glial cells. Since we …

Overcoming the lack of effective treatments and the continuous clinical trial failures in
neurodegenerative drug discovery might require a shift from the prevailing paradigm targeting …

Amyotrophic lateral sclerosis and frontotemporal dementia are overlapping diseases in which
MRI reveals brain structural changes in advance of symptom onset. Recapitulating these …

Aspartate-Glutamate Carrier 1 (AGC1) deficiency is a rare neurological disease caused by
mutations in the solute carrier family 25, member 12 (SLC25A12) gene, encoding for the …

Gene expression is controlled by several epigenetic mechanisms involving post-translational
modification of histones (acetylation, phosphorylation and others). These mechanisms in …